Chemotherapy and Cellular Immunotherapy for the Treatment of IL13Ralpha2 Positive Recurrent or Refractory Brain Tumors
Conditions: Malignant Brain Neoplasm; Recurrent Malignant Brain Neoplasm; Refractory Malignant Brain Neoplasm Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Immunotherapy | Neurology | Research